Vasopressin: a novel target for the prevention and retardation of kidney disease?
- 26 February 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Nephrology
- Vol. 9 (4), 223-239
- https://doi.org/10.1038/nrneph.2013.22
Abstract
After several decades during which little attention was paid to vasopressin and/or urine concentration in clinical practice, interest in vasopressin has renewed with the availability of new, potent, orally active vasopressin-receptor antagonists--the vaptans--and with the results of epidemiological studies evaluating copeptin (a surrogate marker of vasopressin) in large population-based cohorts. Several experimental studies in rats and mice had previously shown that vasopressin, acting via vasopressin V2 antidiuretic receptors, contributes to the progression of chronic kidney disease; in particular, to autosomal dominant polycystic kidney disease. New epidemiological studies now suggest a role for vasopressin in the pathogenesis of diabetes mellitus and metabolic disorders via activation of hepatic V1a and/or pancreatic islet V1b receptors. The first part of this Review describes the adverse effects of vasopressin, as revealed by clinical and experimental studies in kidney diseases, hypertension, diabetes and the metabolic syndrome. The second part provides insights into vasopressin physiology and pathophysiology that may be relevant to the understanding of these adverse effects and that are linked to the excretion of concentrated nitrogen wastes and associated hyperfiltration. Collectively, the studies reviewed here suggest that more attention should be given to the vasopressin-thirst-urine concentration axis in clinical investigations and in patient care. Whether selective blockade of the different vasopressin receptors may provide therapeutic benefits beyond their present indication in hyponatraemia requires new clinical trials.Keywords
This publication has 161 references indexed in Scilit:
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Hydration biomarkers in free-living adults with different levels of habitual fluid consumptionBritish Journal of Nutrition, 2012
- Genetic variation in the vasopressin receptor 1a gene ( AVPR1A ) associates with pair-bonding behavior in humansProceedings of the National Academy of Sciences of the United States of America, 2008
- Vasopressin Antagonists in Polycystic Kidney DiseaseSeminars in Nephrology, 2008
- Cloning and identification of an oxytocin/vasopressin-like receptor and its ligand from insectsProceedings of the National Academy of Sciences of the United States of America, 2008
- Copeptin: clinical use of a new biomarkerTrends in Endocrinology & Metabolism, 2008
- Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressinThe Journal of Experimental Medicine, 2007
- Binding of (3H) SR 49059, a Potent Nonpeptide Vasopressin V1a Antagonist, to Rat and Human Liver MembranesBiochemical and Biophysical Research Communications, 1994
- Familiäre proximal-tubuläre Azotämie: Erhöhte Harnstoff-Plasmakonzentration bei normaler NierenfunktionDeutsche Medizinische Wochenschrift (1946), 1986
- Increased Glomerular Filtration Rate in Patients with Major Burns and Its Effect on the Pharmacokinetics of TobramycinNew England Journal of Medicine, 1978